Immune‐mediated drug‐induced liver injury secondary to Omeprazole: A case report

Hassen, Sara Seife; Ata, Fateen; Bilal, Ammara Bint I; Ali, Mohamed Salih; Petkar, Mahir; Elzouki, Abdel-Naser; Zahid, Muhammad

doi:10.1002/ccr3.3421

Search citation statements

Order By: Relevance

Paper Sections

Select...

Toxic and Drug Induced Liver Injury1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

2024

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

(1 citation statement)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From 2011 to 2020, publications per year were nearly stationary but no reported publications in 2021. Near half of publications were case reports (185)(186)(187)(188)(189), but the others were variety of randomized controlled trials (190,191), prospective (192,193), retrospective (194,195), cohort (196)(197)(198) and observational studies studying the presentation, causes, diagnosis and outcomes of DILI but no studies in liver transplantation in DILI and toxic liver patients.…”

Section: Toxic and Drug Induced Liver Injurymentioning

confidence: 99%

Liver diseases among Arab world, current state and unmet needs, a scoping review

Almansoury,

Abdel-Gawad,

Abdelghani

et al. 2023

Global Gastroenterology

View full text Add to dashboard Cite

Section: Toxic and Drug Induced Liver Injurymentioning

confidence: 99%

Liver diseases among Arab world, current state and unmet needs, a scoping review

Almansoury,

Abdel-Gawad,

Abdelghani

et al. 2023

Global Gastroenterology

View full text Add to dashboard Cite

Omeprazole

2020

Reactions Weekly

View full text Add to dashboard Cite

Evidence for Metabolic Activation of Omeprazole In Vitro and In Vivo

Zhao

Sun

et al. 2022

Chem. Res. Toxicol.

View full text Add to dashboard Cite

Omeprazole (OPZ) is a proton pump inhibitor commonly used for the treatment of gastric acid hypersecretion. Studies have revealed that use of OPZ can induce hepatotoxicity, but the mechanisms by which it induces liver injury are unclear. This study aimed to identify reactive metabolites of OPZ, determine the pathways of the metabolic activation, and define the correlation of the bioactivation with OPZ cytotoxicity. Quinone imine-derived glutathione (GSH), N-acetylcysteine (NAC), and cysteine (Cys) conjugates were detected in OPZ-fortified rat and human liver microsomal incubations captured with GSH, NAC, or Cys. The same GSH conjugates were detected in bile of rats and cultured liver primary cells after exposure to OPZ. Similarly, the same NAC conjugates were detected in urine of OPZ-treated rats. The resulting quinone imine was found to react with Cys residues of hepatic protein. CYP3A4 dominated the metabolic activation of OPZ. Exposure to OPZ resulted in decreased cell survival in cultured primary hepatocytes. Pretreatment with ketoconazole attenuated the susceptibility of hepatocytes to the cytotoxicity of OPZ.

show abstract

Immune‐mediated drug‐induced liver injury secondary to Omeprazole: A case report

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 5 publications

References 34 publications

Liver diseases among Arab world, current state and unmet needs, a scoping review

Liver diseases among Arab world, current state and unmet needs, a scoping review

Omeprazole

Evidence for Metabolic Activation of Omeprazole In Vitro and In Vivo

Contact Info

Product

Resources

About